Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Silo Pharma Inc
(NQ:
SILO
)
1.490
+0.130 (+9.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Silo Pharma Inc
< Previous
1
2
3
4
5
Next >
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO), Sever Pharma Expand Existing Agreement to Include Extrusion of Novel Ketamine Implant Therapeutic
August 15, 2024
Via
Investor Brand Network
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
August 14, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Agreement to Launch New Study of SPU-16 Homing Peptide for Multiple Sclerosis
August 07, 2024
Via
Investor Brand Network
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
August 07, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) to Participate in Upcoming H.C. Wainwright Annual Global Investment Conference
July 26, 2024
Via
Investor Brand Network
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
July 26, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
July 22, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Enters into $2.1M Registered Direct Offering
July 19, 2024
Via
Investor Brand Network
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
July 19, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Enters Device and CMC Development Master Plan to Support IND-Enabling Study of SPC-15
July 18, 2024
Via
Investor Brand Network
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
July 18, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Exclusive Global License to Develop, Manufacture, Commercialize Alzheimer Drug
July 16, 2024
Via
Investor Brand Network
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
July 16, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters License Agreement with Columbia University for Lead Candidate Targeting PTSD, Stress-Induced Anxiety Disorders
July 08, 2024
Via
Investor Brand Network
Exposures
Product Safety
Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
July 08, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Collaborates with CRO Partner to Advance SPC-15 for PTSD
June 26, 2024
Via
Investor Brand Network
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
June 26, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes on $2M Registered Direct Offering, Provides Update on SP-26 Ketamine Implant Therapeutic
June 07, 2024
Via
Investor Brand Network
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
June 07, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 06, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Registered Direct Offering Estimated to Reach $2M
June 05, 2024
Via
Investor Brand Network
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 05, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Pre-IND Submission for Proprietary Treatment for PTSD, Anxiety
June 04, 2024
Via
Investor Brand Network
Exposures
Product Safety
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
June 04, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma’s (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
June 04, 2024
Via
AB Newswire
Exposures
Product Safety
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares ‘Significant Development’ in Depression Study Showing Potential to Extend Remission Period, Prevent Relapse
May 21, 2024
Via
Investor Brand Network
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
May 21, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Announces Participation in FDA Event Exploring Emerging Therapeutic Interest in Ketamine
May 14, 2024
Via
Investor Brand Network
Exposures
Product Safety
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
May 14, 2024
Silo’s SP-26 currently in development utilizes ketamine as primary therapeutic agent
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares Positive Results for PTSD Treatment
April 23, 2024
Via
Investor Brand Network
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.